Get this report today!
Table of Contents
Between now and 2019, a vast range of blockbuster drugs will go off patent, opening the floodgates in the EU to the biosimilars market. Already established there since 2006, biosimilars are set to be worth between $2.25 billion and $4.8 billion by 2015.
The potential is undeniable. Yet even in its advanced state compared to other regulated and unregulated markets, European biosimilars continue to be challenged by issues and hurdles, ranging from development and manufacturing to approval and opposition from originator companies. What lessons are there to be learned?
In Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?, FirstWord Dossier examines the emerging biosimilars market. The report, based on expert interviews and analysis, examines market differences across Europe and different therapeutic areas. The impact of biosimilars on originator companies—and their response—is discussed, as well as strategies biosimilar companies will engage in to expand their market share. And most importantly, the report offers insight into biosimilar deals and what the future holds in the EU.
– Duncan Emerton, Head of Biosimilars, Datamonitor Healthcare Consulting
– Asa Cox, founder of biosimilarlicensing.com
– Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing at Hospira
Talk to Alexandra
+1 71 86 18 43 02
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Triptans consist of a class of drugs called selective 5-hydroxytryptamine subtype 1 (5-HT1) receptor agonists. Migraine headaches are an established and growing market for patient-friendly drug delivery. ...
PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013 Summary GlobalData's "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013" report, provides ...
What are the implications for regulators, biosimilar companies and branded manufacturers? There are few areas of the pharmaceutical market more hotly debated than biosimilars yet the pathway to developing ...
... Hale & tempest how to provide affordable medicines in today S competitive global market dr. Brian w tempest www.Briantempest.Com world generic medicines congress london ...
Reportlinker.com © Copyright 2013. All rights reserved.